Rago, Florencia <br/><br/>
Degron mediated BRM/SMARCA2 depletion uncovers novel combination partners for treatment of BRG1/SMARCA4-mutant cancers.  [electronic resource] 

 -  Biochemical and biophysical research communications  01 2019 
 - 109-116 p.  digital 
<br/><br/> Publication Type: Journal Article 
<br/><br/><label>ISSN: </label>1090-2104 
<br/><br/><label>Standard No.: </label>10.1016/j.bbrc.2018.09.009  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Animals<br/>Antineoplastic Agents--administration & dosage<br/>CRISPR-Cas Systems<br/>Carcinoma, Non-Small-Cell Lung--drug therapy<br/>Cell Line, Tumor<br/>DNA Helicases--genetics<br/>Female<br/>Gene Knockout Techniques<br/>Humans<br/>Isoquinolines--administration & dosage<br/>Lung Neoplasms--drug therapy<br/>Mice<br/>Mice, Nude<br/>Mutation<br/>Myeloid Cell Leukemia Sequence 1 Protein--antagonists & inhibitors<br/>Nuclear Proteins--genetics<br/>Oxidative Phosphorylation--drug effects<br/>Proteolysis<br/>Sulfonamides--administration & dosage<br/>Transcription Factors--antagonists & inhibitors<br/>Xenograft Model Antitumor Assays